# Ulrich‐Frank Pape

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ulrich-frank-pape/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,756 |
| Field | Neuroendocrine Tumor Research Advances |
| h-index | 36 |
| i10-index | 68 |
| Last Known Institution | Semmelweis University |
| OpenAlex ID | https://openalex.org/A5046696433 |
| ORCID iD | 0000-0002-5238-8348 |
| Works | 181 |

## Researcher papers

Showing 12 of 14.

- [Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group](https://scholariq.org/papers/placebo-controlled-double-blind-prospective-randomized-study-on-the-effect-of/)
- [ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site](https://scholariq.org/papers/enets-consensus-guidelines-update-for-the-management-of-distant-metastatic/)
- [Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group](https://scholariq.org/papers/prospective-randomized-multicenter-trial-on-the-antiproliferative-effect-of/)
- [ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas](https://scholariq.org/papers/enets-consensus-guidelines-for-the-management-of-patients-with-neuroendocrine/)
- [Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors](https://scholariq.org/papers/prognostic-relevance-of-a-novel-tnm-classification-system-for-upper/)
- [ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)](https://scholariq.org/papers/enets-consensus-guidelines-for-neuroendocrine-neoplasms-of-the-appendix/)
- [Neuroendocrine tumors of midgut and hindgut origin: Tumor‐node‐metastasis classification determines clinical outcome](https://scholariq.org/papers/neuroendocrine-tumors-of-midgut-and-hindgut-origin-tumor-node-metastasis/)
- [Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome](https://scholariq.org/papers/long-term-teduglutide-for-the-treatment-of-patients-with-intestinal-failure/)
- [ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers](https://scholariq.org/papers/enets-consensus-guidelines-for-the-standards-of-care-in-neuroendocrine-tumors-2/)
- [Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-Octreotate](https://scholariq.org/papers/long-term-hematotoxicity-after-peptide-receptor-radionuclide-therapy-with-sup/)
- [Long-term results of teduglutide treatment for chronic intestinal failure – Insights from a national, multi-centric patient home-care service program](https://scholariq.org/papers/long-term-results-of-teduglutide-treatment-for-chronic-intestinal-failure/)
- [Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure—A Nested Matched Pair Real-World Study](https://scholariq.org/papers/quality-of-life-in-teduglutide-treated-patients-with-short-bowel-syndrome/)

## Researcher topics

- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Clinical Nutrition and Gastroenterology](https://scholariq.org/topics/clinical-nutrition-and-gastroenterology/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Gastrointestinal motility and disorders](https://scholariq.org/topics/gastrointestinal-motility-and-disorders/)

## Researcher university

- [Semmelweis University](https://scholariq.org/institutions/semmelweis-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.